




Claims

1. A compound of Formula I:



wherein:



R^1 is H, -CN, halogen, C_1 - C_4 alkyl, -O-(C_3 - C_5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C_1 - C_4 alkyl), wherein when R^1 is not H, -CN or halogen, R^1 is optionally substituted with one or more halogen;

each R^2 is independently hydrogen, halogen or C_1 - C_4 alkyl;

R^3 is H or F;


R^{21} is H, halogen, C_1 - C_4 alkyl, C_3 - C_5 cycloalkyl or 4- to 6-membered heterocycle;

R^{22} is H, halogen or C_1 - C_2 alkyl;

R^{24} is -O-(C_1 - C_4 alkyl), -O-(C_1 - C_4 alkyl)-O-(C_1 - C_4 alkyl), -O-(C_3 - C_5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R^{24} is optionally substituted with one or more hydroxyl or halogen; and


R^{25} is H, halogen, C_1 - C_4 alkyl or C_3 - C_5 cycloalkyl, wherein R^{25} is optionally substituted with one or more halogen;

wherein the compound is not:





or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition characterized by dysregulation of a fatty acid synthase pathway, wherein the condition is a cancer.

2. Use of a compound of Formula I:



wherein:



R^1 is H, -CN, halogen, C_1 - C_4 alkyl, -O-(C_3 - C_5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C_1 - C_4 alkyl), wherein when R^1 is not H, -CN or halogen, R^1 is optionally substituted with one or more halogen;

each R^2 is independently hydrogen, halogen or C_1 - C_4 alkyl;

R^3 is H or F;


R^{21} is H, halogen, C_1 - C_4 alkyl, C_3 - C_5 cycloalkyl or 4- to 6-membered heterocycle;

R^{22} is H, halogen or C_1 - C_2 alkyl;

R^{24} is -O-(C_1 - C_4 alkyl), -O-(C_1 - C_4 alkyl)-O-(C_1 - C_4 alkyl), -O-(C_3 - C_5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R^{24} is optionally substituted with one or more hydroxyl or halogen; and

R^{25} is H, halogen, C_1 - C_4 alkyl or C_3 - C_5 cycloalkyl, wherein R^{25} is optionally substituted with one or more halogen;

wherein the compound is not:



or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a condition characterized by dysregulation of a fatty acid synthase pathway, wherein the condition is a cancer.

3. The use of claim 2, wherein the cancer is ~~selected from the group consisting of~~ breast cancer; mantle cell lymphoma; renal cell carcinoma; acute myelogenous leukemia (AML); chronic myelogenous leukemia (CML); diffuse large B cell lymphoma (DLBCL); sarcoma; rhabdomyosarcoma; ovarian cancer; endometrial tumors; non small cell lung carcinoma (NSCLC); small cell, squamous, large cell and adenocarcinoma; lung cancer; colon cancer; ore colorectal tumors; KRAS mutated colorectal tumors; gastric carcinomas; hepatocellular

tumors; liver tumors; primary melanomas; pancreatic cancer; prostate carcinoma; thyroid carcinoma; follicular thyroid carcinoma; anaplastic large cell lymphoma (ALCL); hamartomas; angiomyelolipomas, TSC-associated and sporadic lymphangioleiomyomatosis; Cowden's disease (multiple hamartoma syndrome); sclerosing hemangioma; Peutz-Jeghers syndrome (PJS); head and neck cancer; neurofibromatosis; macular degeneration; macular edema; myeloid leukemia; systemic lupus; and autoimmune lymphoproliferative syndrome (ALPS).


4. The use of claim 2, wherein the cancer is a tumor derived from breast, lung, thyroid, lymph node, kidney, ureter, bladder, ovary, teste, prostate, bone, skeletal muscle, bone marrow, stomach, esophagus, small bowel, colon, rectum, pancreas, liver, smooth muscle, brain, spinal cord, nerves, ear, eye, nasopharynx, oropharynx, salivary gland, or heart tissue.

5. The use of claim 4, wherein the cancer is a tumor derived from breast, lung, prostate, colon, rectum, pancreas, liver, or brain tissue.


46. The use of any one of claims 32-5, wherein a second the medicament is for combined administration with an additional therapeutic agent is to be administered, wherein the second additional therapeutic agent is a cancer therapeutic agent selected from paclitaxel, doxorubicin, vincristine, actinomycin D, altretamine, asparaginase, bleomycin, busulfan, cabazitaxel, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, epirubicin, etoposide, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, mitomycin, mitozantrone, oxaliplatin, procarbazine, steroids, streptozocin, taxotere, taemozolomide, thioguanine, thiotepa, tomudex, topotecan, treosulfan, uracil-tegufur, vinblastine, and vindesine, nivolumab, pembrolizumab, MPDL3280A, MEDI4736, olaparib, erlotinib, necitumumab, trastuzumab, pertuzumab, lapatinib, crizotinib, cabozantinib, onartumab, ramucirumab, bevacizumab, enzalutamide, abiraterone, tamoxifen, cobimetinib, vemurafenib, everolimus, lapatinib, trastuzumab, Kadcycla, sirolimus, avastin, nexavar, sutent, exemtesane, femora, enzalutamide, bicalutamide, Tafenlar, and Zelboraf.

7. The use of claim 6, wherein the second therapeutic agent is a cancer therapeutic agent selected from paclitaxel, docetaxel, gemcitabine, and irinotecan.


58. The use of ~~claim 2~~any one of claims 2-7, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, L-Ar is



69. The use of ~~claim 2~~any one of claims 2-7, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, L-Ar is



710. The use of ~~claim 2~~any one of claims 2-7, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, L-Ar is



811. The use of ~~claim 2~~any one of claims 2-10, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R³ is H.

912. The use of ~~claim 2~~any one of claims 2-11, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R¹ is -CN or -O-(C₁-C₄ alkyl), wherein when R¹ is not -CN, R¹ is optionally substituted with one or more halogen; or R¹ is -CN; or R¹ is -O-(C₁-C₄ alkyl) optionally substituted with one or more halogen.

1013. The ~~compound use of~~ ~~claim 2~~any one of claims 2-12, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, each R² is hydrogen.

1114. The use of ~~claim 2~~any one of claims 2-13, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R²¹ is C₁-C₄ alkyl.



1215. The use ~~claim 2~~any one of claims 2-14, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R²² is H or C₁-C₂ alkyl.






~~13~~16. The use of ~~claim 2~~any one of claims 2-15, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R^{24} is -O-(C₁-C₄ alkyl) optionally substituted with one or more hydroxyl or halogen; or R^{24} is -O-(C₁-C₄ alkyl) optionally substituted with one or more hydroxyl.







17. The use of any one of claims 2-15, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R^{24} is -O-(C₁-C₄ alkyl)-O-(C₁-C₄ alkyl), -O-(C₃-C₅ cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R^{24} is substituted with one or more hydroxyl or halogen, or R^{24} is -O-(C₁-C₄ alkyl) substituted with one or more hydroxyl.






~~14~~18. The use of ~~claim 2~~any one of claims 2-17, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R^{25} is -CH₃.


~~15~~19. The use of ~~claim 2~~any one of claims 2-7, wherein the compound of Formula (I) has one of the following structures:












~~16. A pharmaceutical composition comprising a compound of claim 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or diluent.~~

~~1720. The use of claim 2~~any one of claims 2-7, wherein the compound of Formula (I) is:



~~1821. The use of claim 2~~any one of claims 2-7, wherein the compound of Formula (I) is:

